More studies are needed in order to assess functional changes through time. The full safety profile of this new technique is still unknown. ConclusionsĪn autologous full-thickness retinal transplant may improve the anatomical and structural outcome of patients with refractory macular holes. During follow-up, one patient developed mild proliferative vitreoretinopathy and epiretinal membrane without anatomical or functional consequences. Despite a positive trend toward visual recovery ( p = 0.034), after the correction of the alpha value, the change lost its statistical significance. Most patients formed a pseudofovea and normalization of the internal retinal layers. The remaining showed a 44.9% reduction of the initial gap. Six patients with a closed macular hole at the end of the follow-up had complete recovery of the myoid/ellipsoid layer. The closure rate after 12 months of follow-up was 76.92%. We enrolled 13 eyes from 13 patients (mean age: 67.15 years) with refractory macular holes, with a mean base diameter of 1615.38 ± 689.19 µm and a minimum diameter of 964.08 ± 709.77 µm. Statistical analysis was done with a test for repeated measurements and Bonferroni correction, with an alpha value of 0.05 for statistical significance and a Mann-Whitney U test for nonparametric continuous variables. Follow-up was done at 1, 3, 6, and 12 months. All the patients underwent a 23-gauge pars plana vitrectomy with a full-thickness retinal transplant and silicone oil tamponade (5000 cs<). All the patients had a comprehensive ophthalmological examination, which included a best-corrected visual acuity assessment, fundus examination, and optical coherence analysis. We include patients with a clinical diagnosis of refractory macular holes with a minimum diameter of at least 500 µm. The objective of the present study is to assess the anatomical and functional outcomes, as well as the structural change through time, of the optical coherence tomography of patients with refractory macular holes treated with a full-thickness autologous retinal transplant. Shinya Yamanaka, who was awarded a Nobel Prize in physiology or medicine in 2012 for the discovery of iPS cells, heads the research at the university aiming at making the treatment adaptable to many illnesses and injuries.Despite the constant refinement of techniques and surgical aids, extremely large and refractory macular holes continue to have poor surgical outcomes with the current standard of care. In the clinical trials, scientists used iPS cells restored at Kyoto University, which were designed to lower the risk of rejection. The patients, who suffered wet-type age-related macular degeneration that can cause blindness, received transplants of artificially grown retinal cells made from donor iPS cells.Īmong the patients, four have maintained their level of visual acuity after the operations, while one had an improvement in vision, according to the researchers.Ĭompared with using iPS cells from patients themselves, using stocked donor cells reduces the cost and time to nurture cells for transplants, the research team said. We'd like to begin new clinical trials to find out for what type of symptoms the treatment would be highly effective," said project leader Masayo Takahashi, a researcher at the Japanese government-backed Riken institute, in the first detailed report on the patients' post-surgery recovery. "We think we were able to ensure the safety (of the treatment). TOKYO, April 18 (Xinhua) - Japanese researchers said Thursday that the world's first transplant surgeries in 2017 using induced pluripotent stem (iPS) is safe in the long term, as the five patients with severe eye disease were doing well a year after the surgeries, local media reported.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |